Day 1 | Day 2 | Download Brochure | Short Courses
Scientific Advisory Board
Lyle Arnold, Ph.D., CSO & Senior Vice President, R&D, Biocept
Joseph M. Carroll, Ph.D., Business Development, Knight Cancer Institute, Oregon Health Science University
George Netto, M.D., Associate Professor of Pathology, Urology and Oncology, Johns Hopkins University School of Medicine
Recommended Pre-Conference Short Courses*
*Separate registration required
|
TUESDAY, AUGUST 21
7:30 am Registration and Morning Coffee
8:30 Chairperson’s Opening Remarks
Lyle Arnold, Ph.D., CSO & Senior Vice President, R&D, Biocept
8:40 From Assay to Answers to Action: Clinical Implementation of High-Throughput Sequencing for Improved Cancer Care
Olivier Harismendy, Ph.D., Asst. Adj. Professor, Pediatrics, Division of Genome Information Sciences, Moores UCSD Cancer Ctr and UC San Diego Clinical and Translational Research Inst, Univ of California, San Diego
9:10 Circulating Tumor Cells and Plasma as Sample Types for Biomarker Analysis
Lyle Arnold, Ph.D., CSO & Senior Vice President, R&D, Biocept
The rapid advances in next generation sequencing are providing a much greater depth of discovery and analysis for accelerating the path to personalized medicine. The intersection of alternative sample types together with sequencing technologies provides further opportunities to help manage patient care. We have further enabled the use of sequencing with blood based “liquid biopsy” sample types by selectively enriching biomarkers of interest using an assay we call SelectorTM. This allows analysis, using sequencing, of very rare alleles of medical interest. Single nucleotide mutations as low as 0.002% become detectable in a complex genomic background.
9:40 Advanced Molecular Diagnostics Based on Ultrasensitive RNA in situ Hybridization
Yuling Luo, Ph.D., Founder, President & CEO, Advanced Cell Diagnostics, Inc.
RNA biomarkers are traditionally analyzed by “grind-and-bind” assays such as RT-PCR, which loses critical cellular context for clinical interpretation. Recent advances in in situ RNA analysis capable of detecting single RNA molecules in routine clinical specimens may finally enable more advanced RNA-based diagnostics.
9:55 High Sensitivity Detection of Clinically Actionable Mutations in FFPE Tumor Biopsies Using Targeted Deep Sequencing
Diane Ilsley, Ph.D., Marketing Manager, Asuragen, Inc.
Translation of next generation sequencing into routine clinical use requires compatibility with clinical specimens, such as FFPE and FNA tumor biopsies, which pose several challenges for molecular analysis. We have developed a targeted deep sequencing methodology using PCR-based enrichment that enables accurate detection of clinically actionable low-level variants in FFPE samples. Our results demonstrate a strategy that addresses current unmet needs for unbiased and highly sensitive mutation detection in clinical specimens.
10:25 Coffee Break
11:00 Next Generation Sequencing at Genomic Health
Steven Shak, M.D., Chief Medical Officer, Genomic Health
11:30 Clinical Application of Next Generation Sequencing for Actionable Mutations in Cancer
Marilyn M. Li, M.D., Professor, Department of Molecular and Human Genetics, Baylor College of Medicine
Mutation detection in cancer has been a challenge due to the mosaic nature of tumor tissues and the genomic heterogeneity of tumor clones. Targeted NGS permits deep sequencing of hundreds of mutations concurrently. The technology allows the detection of multiple clinically actionable mutations at the same time with high sensitivity and specificity. The low input DNA, short turn around time, and low cost of targeted NGS provide huge potential of clinical utility, including diagnostic and therapeutic applications.
12:00 Clinical Applications of Cancer Genomics
John McPherson, Ph.D., Director, Genome Technologies, Ontario Institute for Cancer Research
Next-generation sequencing (NGS) enables deep sequencing of tumour biopsies to reveal the landscape of somatic mutations. Many detected mutations can help guide therapeutic decisions but the functional consequence of others remain to be elucidated. As data are accumulated in conjunction with functional studies and patient outcome new biomarkers can potentially be revealed.
12:30 Towards a Human Clinical Grade Genome - EdgeBio and The Archon Genomics X PRIZE Presented by Medco
Justin Johnson, Director, Bioinformatics, EdgeBio
12:45 Sponsored Presentation (Opportunities Available)
1:00 Luncheon Presentation
Speaker to be Announced
2:00 Session Break
2:15 Chairperson’s Remarks
George Netto, M.D., Associate Professor of Pathology, Urology and Oncology, Johns Hopkins University School of Medicine
2:20 The Role of Molecular Markers in the Diagnosis of Non-Small Cell Lung Cancer
Peter B. Illei, M.D., Assistant Professor of Pathology, Johns Hopkins University School of Medicine; Director, Immunopathology Laboratory, The Johns Hopkins Hospital, Baltimore, Maryland
Histology and the presence of driver mutations are predictive of response to systemic therapy. Immunohistochemistry is important for accurately classifying tumors, while molecular studies can identify common driver mutations (i.e.: EGFR mutation, EML4-ALK translocation, k-ras mutation, B-Raf mutation, Her2 mutation) that can be targeted. These analyses should be performed in all adenocarcinomas and other non-squamous non-small cell lung carcinomas.
2:50 Human Papillomavirus and Carcinomas of the Head and Neck
Justin A. Bishop, M.D., Assistant Professor of Pathology, Johns Hopkins Bayview Medical Center
This talk will discuss the role of human papillomavirus (HPV) in head and neck cancers. I will briefly touch upon mechanisms of oncogenesis, histopathologic findings, and implications for diagnosis and management.
3:20 Incorporating Next-Gen Sequencing into the Clinical Environment
Anthony P. Shuber, CTO, Predictive Biosciences
We have recently developed a non-invasive assay that uses Next Gen sequencing to detect single mutant molecules of FGFR3 in urine that are indicative of bladder cancer. The superior analytical sensitivity of this assay results in mutation detection in urine that is >90% concordant with that found in tissue. This NGS approach can be applied to other cancer markers and bodily fluids to improve clinical performance and ultimately, patient management.
3:35 Refreshment Break in the Exhibit Hall with Poster Viewing
4:10 Molecular Genetics of Pancreatic Neoplasms: Insights from High-Throughput Sequencing
Laura Wood, M.D., Ph.D., Pathology, Johns Hopkins University School of Medicine
Neoplasms of the pancreas cover a wide clinical spectrum, from benign tumors to the deadliest cancers. Recent large-scale sequencing analyses provided great insights into the unique biology of pancreatic neoplasms, deepening our understanding of tumorigenesis in the pancreas. Moreover, these studies identified several promising targets for the development of novel diagnostics and therapeutics, highlighting the ability of genomic analyses to pinpoint clinically-actionable alterations.
4:40 Renal Cell Carcinoma: Current and Emerging Therapies and Biomarkers
Hans Hammer, M.D., Ph.D., Assistant Professor, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
The treatment paradigm for kidney cancer has changed dramatically over the last decade. Current and emerging therapies and potential biomarkers will be reviewed.
5:10 Wine and Cheese Pairing Welcome Reception in the Exhibit Hall with Poster Viewing
6:10 Close of Day
Day 1 | Day 2 | Download Brochure | Short Courses